Angiogenesis protein therapy with human fibroblast growth factor (fgf-1): results of a phase I open label, dose escalation study in subjects with CAD not eligible for PCI or CABG

被引：0
|
作者：
Wagoner, Lynne E. [1 ]
Merrill, Walter [1 ]
Jacobs, Jack [2 ]
Conway, Ginger [1 ]
Boehmer, John [3 ]
Thomas, Kenneth [2 ]
Stegmann, Thomas [2 ]
机构：
[1] Univ Cincinnati, Cincinnati, OH USA
[2] CVBT, Las Vegas, NV USA
[3] Hershey Med Ctr, Hershey, PA USA
来源：
CIRCULATION | 2007年 / 116卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：443 / 443
页数：1
相关论文
共 50 条
  • [1] Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study
    Laham, RJ
    Chronos, NA
    Pike, M
    Leimbach, ME
    Udelson, JE
    Pearlman, JD
    Pettigrew, RI
    Whitehouse, MJ
    Yoshizawa, C
    Simons, M
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (07) : 2132 - 2139
  • [2] Preliminary results of a dose escalation study of the Fibroblast Growth Factor (FGF) "trap" FP-1039 (FGFR1:Fc) in patients with advanced malignancies
    Tolcher, A.
    Papadopolous, K.
    Patniak, A.
    Heath, E.
    Weise, A.
    Prokop, T.
    Morrone, S.
    Zanghi, J.
    Keer, H. N.
    LoRusso, P.
    EJC SUPPLEMENTS, 2010, 8 (07): : 121 - 121
  • [3] Results of a phase I open label dose escalation study of intracoronary and intravenous basic fibroblast growth factor (rFGF-2) in patients (Pts) with severe ischemic heart disease: 6 months follow-up
    Laham, RJ
    Chronos, NA
    Leimbach, M
    Pearlman, JD
    Pettigrew, R
    Dilsizian, V
    Udelson, J
    Whitehouse, MJ
    Pike, M
    Yoshizawa, C
    Simons, M
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 73A - 73A
  • [4] A phase I/IIa, first time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
    Blackman, Samuel C.
    Gainer, Shelby D.
    Suttle, Benjamin B.
    Skordos, Konstantine W.
    Greshock, Joel D.
    Motwani, Monica
    Roadcap, Lori T.
    Hardwicke, Mary Ann A.
    Wooster, Richard F.
    CANCER RESEARCH, 2012, 72
  • [5] Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
    Nogova, Lucia
    Sequist, Lecia V.
    Garcia, Jose Manuel Perez
    Andre, Fabrice
    Delord, Jean-Pierre
    Hidalgo, Manuel
    Schellens, Jan H. M.
    Cassier, Philippe A.
    Camidge, D. Ross
    Schuler, Martin
    Vaishampayan, Ulka
    Burris, Howard
    Tian, G. Gary
    Campone, Mario
    Wainberg, Zev A.
    Lim, Wan-Teck
    LoRusso, Patricia
    Shapiro, Geoffrey I.
    Parker, Katie
    Chen, Xueying
    Choudhury, Somesh
    Ringeisen, Francois
    Graus-Porta, Diana
    Porter, Dale
    Isaacs, Randi
    Buettner, Reinhard
    Wolf, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) : 157 - +
  • [6] Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
    Goldberg, Avram
    Geppert, Thomas
    Schiopu, Elena
    Frech, Tracy
    Hsu, Vivien
    Simms, Robert W.
    Peng, Stanford L.
    Yao, Yihong
    Elgeioushi, Nairouz
    Chang, Linda
    Wang, Bing
    Yoo, Stephen
    ARTHRITIS RESEARCH & THERAPY, 2014, 16 (01)
  • [7] Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
    Avram Goldberg
    Thomas Geppert
    Elena Schiopu
    Tracy Frech
    Vivien Hsu
    Robert W Simms
    Stanford L Peng
    Yihong Yao
    Nairouz Elgeioushi
    Linda Chang
    Bing Wang
    Stephen Yoo
    Arthritis Research & Therapy, 16
  • [8] A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies
    Lubner, Sam Joseph
    Mullvain, Jacqueline
    Perlman, Scott
    Pishvaian, Michael
    Mortimer, Joanne
    Oliver, Katherine
    Heideman, Jennifer
    Hall, Lance
    Weichert, Jamey
    Liu, Glenn
    CANCER INVESTIGATION, 2015, 33 (10) : 483 - 489
  • [9] Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study
    Cousin, Sophie
    Blay, Jean-Yves
    Garcia, Irene Brana
    de Bono, Johann S.
    Le Tourneau, Christophe
    Moreno, Victor
    Trigo, Jose
    Hann, Christine L.
    Azad, Arun A.
    Im, Seock-Ah
    Cassier, Philippe A.
    French, Christopher A.
    Italiano, Antoine
    Keedy, Vicki L.
    Plummer, Ruth
    Sablin, Marie-Paule
    Hemming, Matthew L.
    Ferron-Brady, Geraldine
    Wyce, Anastasia
    Khaled, Ahmed
    Datta, Antara
    Foley, Shawn W.
    McCabe, Michael T.
    Wu, Yuehui
    Horner, Thierry
    Kremer, Brandon E.
    Dhar, Arindam
    O'Dwyer, Peter J.
    Shapiro, Geoffrey I.
    Piha-Paul, Sarina A.
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (06) : 993 - 1006
  • [10] A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.
    Shapira, Roni
    Weber, Jeffrey S.
    Geva, Ravit
    Sznol, Mario
    Kluger, Harriet M.
    Wong, Deborah J. L.
    Liang, Bertrand C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345